TUMOR IMMUNITY AND AUTOIMMUNITY PRODUCED BY INJECTION OF ANTIGENS MODIFIED BY ADSORBED VIRUS NLM AIDSLINE Important note: Information in this article was accurate in 1981. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


TUMOR IMMUNITY AND AUTOIMMUNITY PRODUCED BY INJECTION OF ANTIGENS MODIFIED BY ADSORBED VIRUS

Cancer Immunol Immunother; 9(3):199-205 1980. Unique Identifier : AIDSLINE ICDB/81694235
Eaton MD; Almquist SJ; Dept. Medical Microbiology, Stanford Univ. Sch. Medicine,; Stanford, CA, 94305

Abstract: An attempt was made to immunize C3H/Bi mice against a syngeneic Gross leukemia virus-induced ascites lymphoma by repeated injections of tumor cell membranes containing adsorbed strain Cal Newcastle disease virus, strain Sendai parainfluenza I virus (SiV), or strain WSN influenza virus (WSN). Mice receiving the membranes with adsorbed viral antigens developed some immunity to challenge with 50, 100, or 500 tumor cells. However, autoimmunity appeared regularly and there were significant numbers of deaths from autoimmune disease. In one experiment, membranes treated with SiV or WSN failed to produce fatal autoimmune disease, but the survival rate after a minimal challenge dose was equal to or less than the control rate. In another experiment, the mortality was lower in mice injected with untreated lymphoma cell membranes than in the mice that received no injection. Complement-fixing and cytotoxic antibodies against uninfected lymphoma and splenocytes were demonstrated in the immunized mice. Autoantibodies to syngeneic RBC were demonstrated by hemolysis in the presence of guinea pig complement. These observations imply that autoimmunity may interfere with tumor immunity. (19 Refs)
Keywords: JOURNAL ARTICLEKWDjournalarticle
810430
M8140004

Copyright © 1981 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1981. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1981. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .